Mira Pharmaceuticals (MIRA) Long-Term Deferred Tax (2022 - 2025)

Mira Pharmaceuticals has reported Long-Term Deferred Tax for 4 years, with the latest figure at $9.6 million in Q4 2025.

• Quarterly Long-Term Deferred Tax rose 39.13% year-over-year to $9.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.6 million (up 39.13% YoY) and the FY2025 annual result came in at $9.6 million, up 39.13% from the prior year.
• Long-Term Deferred Tax climbed to $9.6 million in Q4 2025 per MIRA's latest filing, from $6.9 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $9.6 million in Q4 2025 and troughed at $1291.0 in Q4 2023.
• A 4-year average of $3.9 million and a median of $3.5 million in 2023 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2023 and 2024: Long-Term Deferred Tax slumped 98.61% in 2023, then jumped 534369.4% in 2024.
• Over 4 years, Long-Term Deferred Tax stood at $92736.0 in 2022, then plunged by 98.61% to $1291.0 in 2023, then surged by 534369.4% to $6.9 million in 2024, then jumped by 39.13% to $9.6 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $9.6 million, $6.9 million, and $1291.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.